Children's OTC Medication Measurements Miss the Mark


Labelling and measurement device inconsistencies are rampant among children's OTC medications, with some lacking necessary markings for the product's use.

An examination of 200 of the top-selling cough/cold, allergy, analgesic and gastrointestinal over-the-counter liquid medications for children finds that there have been high levels of variability and inconsistencies regarding medication labeling and measuring devices, according to a study that will appear in the December 15 issue of JAMA. The study is being released early online because of its public health importance.

“In November 2009, the US Food and Drug Administration released new voluntary guidelines to industry groups responsible for manufacturing, marketing, or distributing over-the-counter liquid medications, particularly those intended for use by children. These guidelines were developed in response to numerous reports of unintentional overdoses that were attributed, in part, to products with inconsistent or confusing labels and measuring devices,” according to background information in the article.

H. Shonna Yin, MD, MS, of the New York University School of Medicine and Bellevue Hospital Center, New York, and colleagues conducted a study to determine the prevalence of inconsistent dosing directions and measuring devices among 200 top-selling pediatric oral liquid OTC medications at the time the FDA's guidelines were released. The analysis was conducted for a period of one year, ending October 30, 2009. The sample represents 99 percent of the US market of analgesic, cough/cold, allergy, and gastrointestinal OTC oral liquid products with dosing information for children younger than 12 years.

Among the findings of the researchers, a standardized measuring device was provided for 148 products (74.0 percent). Within these 148 products, nearly all examined (98.6 percent) contained 1 or more inconsistencies between the labeled directions and the accompanying device with respect to doses listed or marked on the device, or text used for unit of measurement. Almost a quarter of products (24.3 percent) lacked necessary markings.

“Among the measuring devices, 81.1 percent included 1 or more superfluous markings. The text used for units of measurement was inconsistent between the product's label and the enclosed device in 89 percent of products. A total of 11 products (5.5 percent) used nonstandard units of measurement, such as drams, cubic centimeters, or fluid ounces, as part of the doses listed,” the authors write.

The researchers also found that across all products, milliliter (143, 71.5 percent) and teaspoon (155, 77.5 percent) were the most frequently used units of measurement. Tablespoon was used in 37 products (18.5 percent). A nonstandard abbreviation for milliliter (not mL) was used by 97 products. Of the products that included an abbreviation, 163 did not define at least one abbreviation.

This study indentifies problems in 3 critical areas, according to the authors: a standardized measuring device should be included with all nonprescription liquid products; within each product, consistency should be ensured between the labeled dosing directions and markings on the associated measuring device; and across products, measurement units, abbreviations, and numeric formats should be standardized.

They add that the risks posed by confusing or inconsistent dosing directions on pediatric OTC medication packaging and measuring devices may vary depending on the nature of the discordant labeling, yet the potential for harm is substantial. More than half of US children are exposed to 1 or more medications in a given week, and more than half of these are OTC medications.

The researchers write that this study provides baseline data for assessing the degree and pace of industry conformity with the guidelines. “At this time, the FDA's guidelines are voluntary, and companies have no legal obligation to follow them. Subsequent systematic product analyses may therefore be helpful to monitor progress, including assessing whether additional regulatory oversight may be needed to ensure practices that best support safe and effective use of OTC medications.”

Source: American Medical Association

Related Videos
Taha Qazi, MD | Credit: Cleveland Clinic
Taha Qazi, MD | Credit: Cleveland Clinic
Taha Qazi, MD | Credit: Cleveland Clinic
Anthony Lembo, MD | Credit: Cleveland Clinic
Prashant Singh, MD | Credit: University of Michigan
Noa Krugliak Cleveland, MD | Credit: University of Chicago
Ali Rezaie, MD | Credit: X
Remo Panaccione, MD | Credit: University of Calgary
Francisca Joly, MD, PhD | Credit: The Transplantation Society
Paul Feuerstadt, MD | Yale School of Medicine
© 2024 MJH Life Sciences

All rights reserved.